SR-142948

SR-142948 is a neurotensin receptor antagonist drug that was developed by Sanofi-Aventis. It has been researched for its potential use in the treatment of schizophrenia, Parkinson's disease, and other neurological disorders.

History

SR-142948 was first synthesized by researchers at Sanofi-Aventis in the late 1990s. It was developed as part of a larger effort to create drugs that could block the effects of neurotensin, a neuropeptide that is thought to play a role in several neurological disorders.

Pharmacology

SR-142948 is a non-peptide antagonist of the neurotensin receptor. It has high affinity for both the NTS1 and NTS2 subtypes of the neurotensin receptor, and has been shown to block the effects of neurotensin in a variety of in vitro and in vivo experiments.

Clinical trials

In preclinical studies, SR-142948 has been shown to have antipsychotic-like effects in animal models of schizophrenia. It has also been shown to reduce the motor symptoms of Parkinson's disease in animal models. However, as of 2021, SR-142948 has not yet been tested in human clinical trials.

Potential therapeutic uses

Based on its pharmacological profile, SR-142948 has potential therapeutic uses in a variety of neurological disorders. These include schizophrenia, where it could potentially be used as a novel antipsychotic drug, and Parkinson's disease, where it could potentially be used to reduce motor symptoms. Other potential uses include the treatment of anxiety disorders, depression, and drug addiction.

See also

• Neurotensin
• Neurotensin receptor
• Schizophrenia
• Parkinson's disease